Pharmacological management of hypertrophic cardiomyopathy: From bench to bedside
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and most of the indications in the curr...
Հիմնական հեղինակներ: | Palandri, C, Santini, L, Argirò, A, Margara, F, Doste, R, Bueno-Orovio, A, Olivotto, I, Coppini, R |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
Springer
2022
|
Նմանատիպ նյութեր
-
Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
: Coleman, JA, և այլն
Հրապարակվել է: (2024) -
Remodelling of potassium currents underlies arrhythmic action potential prolongation under beta-adrenergic stimulation in hypertrophic cardiomyopathy
: Doste, R, և այլն
Հրապարակվել է: (2022) -
Electrophysiological mechanisms underlying T wave pseudonormalisation on stress ECGs in hypertrophic cardiomyopathy
: Coleman, J, և այլն
Հրապարակվել է: (2023) -
Mechanisms of ischaemia-induced arrhythmias in hypertrophic cardiomyopathy: a large-scale computational study
: Coleman, JA, և այլն
Հրապարակվել է: (2024) -
Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: a Translational Study
: Coppini, R, և այլն
Հրապարակվել է: (2019)